United States: Rule Review - Obviousness-Type Double Patenting

The Uruguay Round Agreements Act (URAA), Pub. L. 103-465, 108 Stat. 4809 (effective June 8, 1995), installed a twenty-year U.S. patent term from the earliest-claimed priority date, modifying the previous seventeen-year term calculated from the date of patent issuance.1  That change eliminated a perceived abuse—sometimes called "submarine patenting" or "evergreening"—wherein the use of continuing applications allowed claiming of previously disclosed features many, many years later, since patent expiration was calculated from the date of issuance.  In that former context, the prohibition against obviousness-type double patenting (OTDP) was a check ensuring that patentees could not obtain more than one patent based on merely unpatentable variations, effectively extending the monopoly on the same basic invention.   

When OTDP, also known as "non-statutory double patenting," was raised by AbbVie Inc. as a defense in an infringement suit brought by The Mathilda and Terence Kennedy Institute of Rheumatology Trust ("Kennedy"), the policy justification for the doctrine post-URAA was questioned.2  Kennedy argued that the rationale for the rule no longer exists and that the doctrine should be discarded.  The Federal Circuit, however, reaffirmed in its unanimous opinion that compelling reasons militate in favor of OTDP today:

It is designed to prevent an inventor from securing a second, later expiring patent for the same invention.  That problem still exists. . . .  [W]here, as here, the applicant chooses to file separate applications for overlapping subject matter and to claim different priority dates for the applications, the separate patents will have different expiration dates since the patent term is measured from the claimed priority date.3

In AbbVie, both patents at issue were directed towards methods of treating rheumatoid arthritis by co-administering two drugs—a disease-modifying antirheumatic drug (methotrexate) and an antibody (anti-TNF antibodies).  Kennedy sought and secured two patents on this combination therapy: it claimed the priority date of October 8, 1992 (the filing date of an earlier application), for U.S. Patent No. 6,270,766 ("the '766 patent"), and a later priority date, August 1, 1996 (the filing date of the '766 patent), for U.S. Patent No. 7,846,442 ("the '442 patent"), "so that the '422 patent would expire after the '766 patent."4  This timing made for a six-year difference in patent term.  "When such situations arise," explained the court, "the doctrine of obviousness-type double patenting ensures that a particular invention (and obvious variants thereof) does not receive an undue patent term extension."5  The Federal Circuit thus made explicit at least one post-URAA application for OTDP: "[T]he doctrine of obviousness-type double patenting continues to apply where two patents that claim the same invention have different expiration dates."6 

In analyzing whether the claimed matter was patentably distinct, the Federal Circuit affirmed the district court's finding that the two inventions were not.  As a first step, claim construction, the Federal Circuit agreed that the "co-administering" limitation did not mean "administration of the antibody alone after discontinuing treatment with methotrexate."7  "Put simply," based on the specification of the '766 patent, "co-administration" meant "administration of both drugs at the same time," and "cannot include patients who discontinued methotrexate as Kennedy contends."8  The Federal Circuit then assumed, without deciding, that Kennedy's definition of the term "active disease"—"the presence of six or more swollen joints plus at least three of four secondary criteria"—was correct for the purposes of its OTDP analysis.9 Given Kennedy's definition of "active disease," the court noted that "the genus claimed in the '766 patent (treating all patients in need thereof) is broader than the species claimed in the '442 patent (treating patients with 'active disease,' i.e., particularly sick patients)."10  While Kennedy admitted that the claims of the '442 patent were encompassed by the claims of the '766 patent, Kennedy argued that the species claims were separately patentable.11  The Federal Circuit reminded that, indeed, "a narrow species can be non-obvious and patent eligible despite a patent on its genus," but that "not every species of a patented genus is separately patentable."12 

In the second step of the OTDP analysis—whether the differences in the subject matter between the claims render them patentably distinct—the Federal Circuit found the later-expiring claims were obvious over the earlier claims.  In particular, the court found that the later claims of the '442 patent applying to sicker patients with "active disease" were specific as compared to the '766 patent claims directed to a broader patient population.  According to the court, "species are unpatentable when prior art disclosures describe the genus containing those species such that a person of ordinary skill in the art would be able to envision every member of the class."13 

The court further found that there were no unexpected results with respect to the "active disease" group when compared to the known utility disclosed in the specification of the '766 patent.14  The court was free to "look to a reference patent's disclosures of utility to determine the question of obviousness," even if the reference patent's specification cannot technically be used as prior art in the OTDP analysis.15  The Federal Circuit stated that "[w]e have repeatedly approved examination of the disclosed utility of the invention claimed in an earlier patent to address the question of obviousness."16  Accordingly, the claims of the '422 patent were deemed to have been obvious over the '766 patent claims, rendering them invalid for OTDP.17 

The Federal Circuit has addressed the issue of OTDP several times over the last two decades.18  As evidenced in the AbbVie decision, the doctrine can reach some very specific circumstances, including where two patents claim the same invention, but have different expiration dates due to different priority assertions.


1 Because of the URAA, patents filed on or before June 15, 1995, have a base term of seventeen years from the date of issue; patents filed after June 15, 1995, have a base term of twenty years from the date of filing.

2 See AbbVie Inc. v. Mathilda & Terence Kennedy Inst. of Rheumatology Trust, No. 2013-1545, slip op. at 10-11 (Fed. Cir. Aug. 21, 2014).

3 Id. at 11 (citations omitted).

4 Id. at 11-12 n.2. 

5 Id. at 11-12. 

6 Id. at 13.

7 Id. at 15. 

8 Id. at 17. 

9 Id. at 19-20.

10 Id. at 20-21.

11 Id. at 4. 

12 Id. at 23.

13 Id. at 24. 

14 Id. at 26. 

15 Id. ("[W]hile . . . it is impermissible to treat a patent disclosure as though it were prior art in a double patenting inquiry, . . . the disclosure may be used . . . to answer the question whether claims merely define an obvious variation of what is earlier disclosed and claimed." (citation and internal quotation marks omitted)).

16 Id. at 26-27 (citing Geneva Pharm., Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373, 1386 (Fed. Cir. 2003)).

17 Id. at 28. 

18 See, e.g., Gilead Scis., Inc. v. Natco Pharma Ltd., 753 F.3d 1208 (Fed. Cir. 2014); Sun Pharm. Indus., Ltd. v. Eli Lilly & Co., 611 F.3d 1381 (Fed. Cir. 2010); In re Fallaux, 564 F.3d 1313 (Fed. Cir. 2009); In re Basell Poliolefine Italia S.P.A., 547 F.3d 1371, 1375 (Fed. Cir. 2008); In re Metoprolol Succinate Patent Litig., 494 F.3d 1011, 1016 (Fed. Cir. 2007); Eli Lilly & Co. v. Barr Labs., Inc., 251 F.3d 955, 967 (Fed. Cir. 2001); In re Berg, 140 F.3d 1428, 1433 (Fed. Cir. 1998); In re Emert, 124 F.3d 1458 (Fed. Cir. 1997). 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.